The European Commission announced on Thursday that it has imposed fines totaling 13.4 million euros (approximately $14.1 million) on five pharmaceutical companies, marking the conclusion of their antitrust investigation.
The Commission levied penalties on Alkaloids of Australia, Alkaloids Corporation, Boehringer, Linnea, and Transo-Pharm for their involvement in a cartel that aimed to manipulate the minimum price of a crucial ingredient used in the production of abdominal antispasmodic drugs.
The substance at the center of this cartel was identified as N-Butylbromide Scopolamine/Hyoscine, referred to as ‘SNBB.’ SNBB serves as a vital component in the manufacturing of the abdominal antispasmodic drug Buscopan and its generic variations.
The Commission’s extensive investigation brought to light that these six companies had cooperated in fixing the minimum sales price of SNBB for their customers, which primarily included distributors and generic drug manufacturers. Additionally, they had engaged in the allocation of quotas and exchanged commercially sensitive information.
Read more: Pharma Giant Charged With Price-Fixing In Generics Probe
The fines imposed on these pharmaceutical companies were determined in line with the Commission’s 2006 Guidelines on fines. These guidelines provide a structured framework for calculating penalties in cases of antitrust violations.
The Commission considered various factors when setting the fines, including the value of SNBB sales associated with the violation, the complexity and multifaceted nature of the antitrust infringement, the geographic extent of the cartel’s operations, and the duration of their illicit activities.
Source: Reuters
Featured News
Ropes & Gray Welcomes New Partner to Boston Antitrust Practice
Nov 4, 2024 by
CPI
Private Equity Giants Eye Minority Stake in Intel’s Altera Chip Unit
Nov 4, 2024 by
CPI
Michael Jordan’s NASCAR Antitrust Case Kicks Off in Federal Court
Nov 4, 2024 by
CPI
Fifth Circuit Questions FTC’s Authority in Intuit’s Challenge to Internal Adjudication
Nov 4, 2024 by
CPI
EU Antitrust Decision on Novo Holdings’ Catalent Acquisition Set for December
Nov 4, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI